Dr. Barzi on the Need for More Sensitive MRD Testing in CRC
Afsaneh Barzi, MD, PhD, discusses the need for more sensitive minimal residual disease testing in colorectal cancer.
Dr. Barzi on Utilizing VEGF Inhibitors Plus Immunotherapy in MSS mCRC
Afsaneh Barzi, MD, PhD, discusses the combination of VEGF inhibitors and immunotherapy in microsatellite stable metastatic colorectal cancer.
Final Thoughts on Effective Therapy and Financial Toxicity
Experts in cancer management share their final thoughts on effective treatment and individualized care vs financial toxicity.
Innovation of Therapies vs Disruptive Pricing
A panel of experts debate the cost of innovation vs disruptive pricing of therapy.
Significance of PD-L1/PD-1 Testing in NSCLC
A panel of experts in cancer treatment review the need for PD-1/PD-L1 testing for immunotherapy.
Impact of Immunotherapy on Standard of Care for NSCLC and GI Cancers
Experts in cancer care management review PD-1/PD-L1 immunotherapy for patients with NSCLC and GI cancers.
Review of AENEAS Trial and Similar Agents
Experts in cancer care review the phase 3 AENEAS trial with aumolertinib and the cost-effectiveness.
EGFR-Targeted TKIs in NSCLC and Cost
Mark Socinski, MD, Gilberto Lopes, MD, and Jack West, MD, provide an overview of the role of EGFR-targeted TKIs in NSCLC and the costs.
Impact of Payers on the Costs of Drugs
Jack West, MD, and Gilberto Lopes, MD, share their thoughts on the impact of payers when dealing with the cost of treatments.
Personalized Therapies Based on Innovation and Affordability
Gilberto Lopes, MD, and Afsaneh Barzi, MD, PhD, discuss personalized treatment plans based on innovative therapies and affordability.
Role of Financial Toxicity on Treatment Decisions
Experts in various specialties of oncology management share their insights on the role of financial toxicity on making treatment decisions for patients.
Definition of Financial Toxicity
Jack West, MD, Gilberto Lopes, MD, and Afsaneh Barzi, MD, PhD, provide a definition for financial toxicity.
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
2 Clarke Drive Cranbury, NJ 08512